User profiles for "author:Sarika Jain"

Sarika Jain (SMIEEE)

- Verified email at nitkkr.ac.in - Cited by 1576

Sarika Jain

- Verified email at ggn.amity.edu - Cited by 195

Sarika jain

- Verified email at dsims.org.in - Cited by 190

Present and future of semantic web technologies: a research statement

A Patel, S Jain - International Journal of Computers and …, 2021 - Taylor & Francis
Semantic web and its technologies have been eyed in many fields. They have the capacity
to organize and link data over the web in a consistent and coherent way. Semantic web …

Research on work-family balance: A review

S Jain, S K. Nair - Business perspectives and Research, 2013 - journals.sagepub.com
In the current globalized era, an increasing number of firms in the services sector require
employees to work longer, frequently interact with customers and work across varied time …

Eribulin mesylate

S Jain, LT Vahdat - Clinical Cancer Research, 2011 - AACR
Eribulin mesylate, a nontaxane, completely synthetic microtubule inhibitor, has recently
been approved by the US Food and Drug Administration as third-line treatment of metastatic …

[HTML][HTML] New clonal strain of Candida auris, Delhi, India: new clonal strain of Candida auris, Delhi, India

A Chowdhary, C Sharma, S Duggal… - Emerging infectious …, 2013 - ncbi.nlm.nih.gov
A new clonal strain of Candida auris is an emerging etiologic agent of fungemia in Delhi,
India. In 12 patients in 2 hospitals, it was resistant to fluconazole and genotypically distinct …

[HTML][HTML] Early local therapy for the primary site in de novo stage IV breast cancer: results of a randomized clinical trial (EA2108)

SA Khan, F Zhao, LJ Goldstein, D Cella… - Journal of Clinical …, 2022 - ncbi.nlm.nih.gov
PURPOSE Distant metastases are present in 6% or more of patients with newly diagnosed
breast cancer. In this context, locoregional therapy for the intact primary tumor has been …

A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: a trial of the …

SA Khan, F Zhao, LJ Solin, LJ Goldstein, D Cella… - 2020 - ascopubs.org
LBA2 Background: About 6% of newly diagnosed breast cancer patients present with Stage
IV disease and an intact primary tumor (IPT). Locoregional treatment (LRT) for the IPT is …

STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90α and β in multiple myeloma cells, which critically contribute to tumor-cell survival

M Chatterjee, S Jain, T Stühmer, M Andrulis… - Blood, 2007 - ashpublications.org
The combined blockade of the IL-6R/STAT3 and the MAPK signaling pathways has been
shown to inhibit bone marrow microenvironment (BMM)–mediated survival of multiple …

Concordance of genomic alterations by next-generation sequencing in tumor tissue versus circulating tumor DNA in breast cancer

YK Chae, AA Davis, S Jain, C Santa-Maria… - Molecular cancer …, 2017 - AACR
While identifying genomic alterations in tumor tissue is the current gold-standard technique
for molecular profiling, circulating tumor DNA (ctDNA) represents a noninvasive method of …

Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy

S Jain, AN Shah, CA Santa-Maria, K Siziopikou… - Breast cancer research …, 2018 - Springer
Purpose Activation of the phosphoinositide 3-kinase (PI3K) pathway is an important
resistance mechanism to anti-HER2 therapies. This study aimed to assess the safety and …

Trends, problems and solutions of recommender system

S Jain, A Grover, PS Thakur… - International …, 2015 - ieeexplore.ieee.org
In this era of web, we have a huge amount of information overloaded over Internet. It
becomes a herculean task for the user to get the relevant information. To some extent, the …